Apellis Pharmaceuticals, Inc. (APLS) Financials
APLS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 788.7 million | 594.2 million |
2023-09-30 | 818.2 million | 585.9 million |
2023-06-30 | 915.6 million | 570.2 million |
2023-03-31 | 978.9 million | 566.7 million |
APLS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -98.0 million | 26.2 million |
2023-09-30 | -169.1 million | 21.6 million |
2023-06-30 | -150.5 million | 29.3 million |
2023-03-31 | -177.9 million | 28.8 million |
APLS Net Income
No data available :(
APLS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 352.3 million | - | 17.9 million |
2023-09-30 | 452.4 million | - | 16.6 million |
2023-06-30 | 616.3 million | - | 17.9 million |
2023-03-31 | 765.1 million | - | 19.1 million |
APLS Shares Outstanding
APLS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 95000 | 69.3 million | 141.7 million | - |
2023-09-30 | 47000 | 79.4 million | 145.6 million | - |
2023-06-30 | 372000 | 95.7 million | 111.4 million | - |
2023-03-31 | 259000 | 110.0 million | 102.1 million | - |
APLS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 146.4 million | 19.9 million |
2023-09-30 | 99.2 million | 22.4 million |
2023-06-30 | 95.0 million | 8.4 million |
2023-03-31 | 44.8 million | 7.8 million |
APLS
Price: $47.28
52 week price:
Earnings Per Share: -4.45 USD
P/E Ratio: -12.87
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.2 million
Ebitda: -11.6 millionMarket Capitalization: 6.9 billion